Mukund Seshadri1, Nuno T Sacadura, Tonya Coulthard. 1. Department of Pharmacology and Therapeutics, Preclinical Imaging Laboratory, Roswell Park Cancer Institute, Buffalo, NY, USA. Mukund.Seshadri@roswellpark.org
Abstract
BACKGROUND: The overall goal of this study was to non-invasively monitor changes in blood flow of squamous cell carcinoma of the head and neck (SCCHN) xenografts using contrast-enhanced magnetic resonance (MR) and ultrasound (US) imaging. METHODS: Experimental studies were performed on mice bearing FaDu tumors and SCCHN xenografts derived from human surgical tissue. MR examinations were performed using gadofosveset trisodium at 4.7T. Change in T1-relaxation rate of tumors (ΔR1) and tumor enhancement parameters (amplitude, area under the curve-AUC) were measured at baseline and 24 h after treatment with a tumor-vascular disrupting agent (tumor-VDA), 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) and correlated with tumor necrosis and treatment outcome. CE-US was performed using microbubbles (Vevo MicroMarker®) to assess the change in relative tumor blood volume following VDA treatment. RESULTS: A marked decrease (up to 68% of baseline) in T1-enhancement of FaDu tumors was observed 1 day after VDA therapy indicative of a reduction in blood flow. Early (24 h) vascular response of individual tumors to VDA therapy detected by MRI correlated with tumor necrosis and volume estimates at 10 days post treatment. VDA treatment also resulted in a significant reduction in AUC and amplitude of patient tumor-derived SCCHN xenografts. Consistent with MRI observations, CE-US revealed a significant reduction in tumor blood volume of patient tumor-derived SCCHN xenografts after VDA therapy. Treatment with VDA resulted in a significant tumor growth inhibition of patient tumor derived SCCHN xenografts. CONCLUSIONS: These findings demonstrate that both CE-MRI and CE-US allow monitoring of early changes in vascular function following VDA therapy. The results also demonstrate, for the first time, potent vascular disruptive and antitumor activity of DMXAA against patient tumor-derived head and neck carcinoma xenografts.
BACKGROUND: The overall goal of this study was to non-invasively monitor changes in blood flow of squamous cell carcinoma of the head and neck (SCCHN) xenografts using contrast-enhanced magnetic resonance (MR) and ultrasound (US) imaging. METHODS: Experimental studies were performed on mice bearing FaDu tumors and SCCHN xenografts derived from human surgical tissue. MR examinations were performed using gadofosveset trisodium at 4.7T. Change in T1-relaxation rate of tumors (ΔR1) and tumor enhancement parameters (amplitude, area under the curve-AUC) were measured at baseline and 24 h after treatment with a tumor-vascular disrupting agent (tumor-VDA), 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) and correlated with tumor necrosis and treatment outcome. CE-US was performed using microbubbles (Vevo MicroMarker®) to assess the change in relative tumor blood volume following VDA treatment. RESULTS: A marked decrease (up to 68% of baseline) in T1-enhancement of FaDu tumors was observed 1 day after VDA therapy indicative of a reduction in blood flow. Early (24 h) vascular response of individual tumors to VDA therapy detected by MRI correlated with tumor necrosis and volume estimates at 10 days post treatment. VDA treatment also resulted in a significant reduction in AUC and amplitude of patienttumor-derived SCCHN xenografts. Consistent with MRI observations, CE-US revealed a significant reduction in tumor blood volume of patienttumor-derived SCCHN xenografts after VDA therapy. Treatment with VDA resulted in a significant tumor growth inhibition of patienttumor derived SCCHN xenografts. CONCLUSIONS: These findings demonstrate that both CE-MRI and CE-US allow monitoring of early changes in vascular function following VDA therapy. The results also demonstrate, for the first time, potent vascular disruptive and antitumor activity of DMXAA against patienttumor-derived head and neck carcinoma xenografts.
Authors: K Turetschek; E Floyd; T Helbich; T P Roberts; D M Shames; M F Wendland; W O Carter; R C Brasch Journal: J Magn Reson Imaging Date: 2001-09 Impact factor: 4.813
Authors: Lise Bentzen; Peter Vestergaard-Poulsen; Thomas Nielsen; Jens Overgaard; Atle Bjørnerud; Karen Briley-Saebø; Michael R Horsman; Leif Ostergaard Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-15 Impact factor: 7.038
Authors: Jennifer C Sullivan; Bin Wang; Erika I Boesen; Gerard D'Angelo; Jennifer S Pollock; David M Pollock Journal: Am J Physiol Renal Physiol Date: 2009-05-06
Authors: Mukund Seshadri; Mihai Merzianu; Haikuo Tang; Nestor R Rigual; Maureen Sullivan; Thom R Loree; Saurin R Popat; Elizabeth A Repasky; Bonnie L Hylander Journal: Cancer Biol Ther Date: 2009-12-19 Impact factor: 4.742
Authors: Ravikumar Aalinkeel; Bindukumar Nair; Chih-Kuang Chen; Supriya D Mahajan; Jessica L Reynolds; Hanguang Zhang; Haotian Sun; Donald E Sykes; Kailash C Chadha; Steven G Turowski; Katelyn D Bothwell; Mukund Seshadri; Chong Cheng; Stanley A Schwartz Journal: Immunology Date: 2016-08 Impact factor: 7.397
Authors: Elena Kurenova; Deniz Ucar; Jianqun Liao; Michael Yemma; Priyanka Gogate; Wiam Bshara; Ulas Sunar; Mukund Seshadri; Steven N Hochwald; William G Cance Journal: Cell Cycle Date: 2014 Impact factor: 4.534
Authors: Margaret Folaron; James Kalmuk; Jaimee Lockwood; Costakis Frangou; Jordan Vokes; Steven G Turowski; Mihai Merzianu; Nestor R Rigual; Maureen Sullivan-Nasca; Moni A Kuriakose; Wesley L Hicks; Anurag K Singh; Mukund Seshadri Journal: Oral Oncol Date: 2013-07-23 Impact factor: 5.337
Authors: Reshmi Rajendran; Wei Huang; Annie Mei Yee Tang; Jie Ming Liang; Stephanie Choo; Torsten Reese; Hannes Hentze; Susan van Boxtel; Adam Cliffe; Keith Rogers; Brian Henry; Kai Hsiang Chuang Journal: Cancer Med Date: 2014-01-06 Impact factor: 4.452
Authors: Laurie J Rich; Jossana A Damasco; Julia C Bulmahn; Hilliard L Kutscher; Paras N Prasad; Mukund Seshadri Journal: Cancers (Basel) Date: 2020-11-06 Impact factor: 6.639